CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report).

Evercore ISI analyst Liisa Bayko maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target ...

CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.

Editas Medicine (EDIT) has been downgraded to market perform from outperform by Raymond James due in part to extended ...

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?